TLC Vision 8-K Issues First Quarter 2008 EPS Guidance of $0.07

News Release	Contact:
For Immediate Release	James J. Hyland, VP Investor Relations (636) 534-2369 Email: investor.relations@tlcvision.com

TLCVisionReports 2007 Same-Store Procedure Growth up 7%

Issues First Quarter 2008 EPS Guidance of $0.07

ST. LOUIS, MO, March 12, 2008:TLC Vision Corporation(NASDAQ:TLCV; TSX:TLC), North America’s premier eye care services company, today announced results for the fourth quarter and full-year ended December 31, 2007 and offered guidance for the first quarter of 2008.

Jim Wachtman, President and Chief Executive Officerof TLCVision, commented, “TLC made great strides during 2007, despite the fact that it was a year of transition and investment for the Company. Our revenues were up across all three business segments. At the same time, we completed some significant strategic goals: implemented a new refractive strategy, simplified our overall business and improved our operating discipline, refined our strategic focus, and strengthened our executive leadership team. Overall, we reinforced our position as a leading competitor for 2008 and beyond.

During 2007 and the first quarter of 2008, we not only successfully repositioned 54 of our centers to our new refractive strategy, we also significantly increased consumer awareness of the TLC brand in the marketplace. Recent consumer awareness studies indicate an increased likelihood for consumers to consider TLC for LASIK over our competitors. Use of Tiger Woods in our consumer advertising has greatly enhanced the TLC image of trust and quality, and our direct to consumer message is well-positioned in the marketplace. As a result of our multi-pronged marketing strategy, we delivered 6.7% same-store procedure growth and 13.6% overall procedure growth in our repositioned centers, well above industry growth rates.

Our first quarter performance for 2008 has been very strong. As we announced earlier this quarter, the Company recorded a 14.3% increase in same-store refractive center procedures for January. In addition, we anticipate first quarter 2008 same-store procedure volume will show absolute growth well in excess of industry levels. We anticipate that first quarter 2008 revenues will be approximately $89 million and first quarter 2008 EPS will be approximately $0.07 per fully diluted share. We will continue to make progress in 2008 as we now have the right strategy, the right people and the right business model in place.”

Fourth Quarter 2007 Results and Highlights

• Revenue for the fourth quarter was $66.3 million, a 5.7% increase over prior year revenue of $62.7 million. *Pro forma revenue, including revenue from discontinued operations for the three months ended December 31, 2007 was $67.0 million, compared to $63.5 million for the prior year period, an increase of 5.4%.

• Refractive Centers revenue increased by 4.8% to $36.3 million on the strength of higher center procedures (up 2.5% on a same store basis to 20,800 for majority-owned centers). Total center procedures including minority-owned centers) increased 1.1% to 24,800.

oDoctor Services revenue increased 4.0% to $23.3 million.
oEye Care revenue increased 18% to $6.7 million.

• TLC opened one new de novo refractive center in Kennesaw, Georgia and announced the opening of its new Toronto, Ontario center in Q1 2008.

• The Company completed the sale of its interest in Oxford Eye Surgery Center (Oxford, MS) on December 31, 2007. Combined with the sale of its Midland, TX ambulatory surgery center (sold in the third quarter of 2007) and the recently announced sale of its interest in the Rockland Surgery Center (Wilmington, DE), this reduces the number of stand-alone ambulatory surgery centers in the Company’s portfolio to five.

• Consolidated net loss for the fourth quarter was ($25.3) million ($0.51 per diluted share), compared to a net loss of ($2.4) million from the prior year period. The consolidated quarterly net loss includes non-cash charges from the Company’s interest in OccuLogix, Inc. ($6.6 million) and impairment and restructuring charges ($6.5 million).

• *Pro forma net loss before AMD, excluding the charges noted above, as well as normalizing interest expense and income taxes, was ($6.8) million, or ($0.14) per diluted share, compared to a net loss of ($1.9) million, or ($0.04) per diluted share, in the prior year period.

• Fourth quarter operating cash flow was $1.5 million, or $0.03 per share, compared to $3.0 million, or $0.04 per share, in the prior year period.

Full-Year 2007 Results

• Revenue for the twelve months ended December 31, 2007 was $298.4 million, compared to $277.8 million for the prior year period, an increase of 7.4%. *Pro forma revenue, including revenue from discontinued operations for the twelve months ended December 31, 2007 was $301.9 million, compared to $281.8 million for the prior year period, an increase of 7.1%.

• Consolidated net loss was ($43.5) million ($0.74 per fully diluted share) compared to net income of $11.5 million, or $0.17 per fully diluted share, for the prior year period, and reflects the impact of the non-cash charges from the Company’s interest in OccuLogix, Inc. ($12.5 million) and impairment and restructuring charges ($21.0 million).

• *Pro forma net loss before AMD, excluding the charges noted above, as well as normalizing interest expense and income taxes, was ($1.2) million, or ($0.02) per diluted share, compared to net income of $12.5 million, or $0.21 per diluted share, in the prior year period.

• Year-to-date operating cash flow was $31.3 million, or $0.53 per share, compared to $38.4 million, or $0.55 per share, in the prior year period. The primary reason for the decrease was the incremental investment in the Refractive Centers business.

• As previously announced, the Company completed a recapitalization in June, prior to a general downturn in the overall financial markets in the second half of 2007.  The recapitalization allowed TLC to return $115 million in immediate value to shareholders.

Wachtman continued. “While we are concerned about the current trends in the overall consumer economy, we remain encouraged about TLC’s market position and strategy and believe that the steps we have taken throughout 2007 will continue to drive increased market penetration and above-average industry growth going forward.”

* Pro-forma results are presented to facilitate a comparison of current year and prior year results. The calculations of pro-forma results are not specified by United States generally accepted accounting principles. Our calculations of pro-forma results may not be comparable to similarly–titled measures of other companies. A reconciliation of reported net income to pro-forma net income for both the quarter and twelve months is included in the attached Consolidated Statements of Operation.

Conference Call

TLCVisioninvites all interested parties to participate in a conference call during which time the financial and operating results will be discussed. The call will be held today, at 9:00 a.m. Eastern Standard Time. To participate, please dial 866-852-2121 or 416-641-6119 (international callers). The call will be broadcast live on the Company’s web site atwww.tlcv.com under the “Webcasts” link in the Investor Relations section.

A replay of the conference call will be available until March 26, 2008. To access the replay, dial 800-408-3053 or 416-695-5800 (international callers) and enter the pass code: 3251532. The call will also be archived on the Company’s web site atwww.tlcv.com under the “Webcasts” link in the Investor Relations section.

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, Section 21E of the U.S. Securities Exchange Act of 1934 and Canadian Provincial Securities Laws, which statements can be identified by the use of forward looking terminology, such as “may”, “will”, “expect”, ”intend”, “anticipate”, “estimate”, “predict”, “plans” or “continue” or the negative thereof or other variations thereon or comparable terminology referring to future events or results. We caution that all forward-looking information is inherently uncertain and that actual results may differ materially from the assumptions, estimates or expectations reflected in the forward-looking information. A number of factors could cause actual results to differ materially from those in forward-looking statements, including but not limited to economic conditions, the level of competitive intensity for laser vision correction, the market acceptance of laser vision correction, concerns about potential side effects and long term effects of laser vision correction, the ability to maintain agreements with doctors on satisfactory terms, quarterly fluctuation of operating results that make financial forecasting difficult, the volatility of the market price of our common shares, profitability of investments, successful execution of our direct-to-consumer marketing programs, the ability to open new centers, the reliance on key personnel, medical malpractice claims and the ability to maintain adequate insurance therefore, claims for federal, state and local taxes, compliance with industry regulation, compliance with U.S. and Canadian healthcare regulations, disputes regarding intellectual property, many of which are beyond our control.

Therefore, should one or more of theses risks materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary significantly from what we currently foresee. Accordingly, we warn investors to exercise caution when considering any such forward-looking information herein and to not place undue reliance on such statements and assumptions. We are under no obligation (and we expressly disclaim any such obligation) to update or alter any forward-looking statements or assumptions whether as a result of new information, future events or otherwise, except as required by law.

See the Company’s reports filed with the Canadian Securities Regulators and the U.S. Securities and Exchange Commission from time to time for cautionary statements identifying important factors with respect to such forward looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward looking statements. TLCVisionassumes no obligation to update the information contained in this press release.

About TLCVision

TLCVision is North America’s premier eye care services company, providing eye doctors with the tools and technologies needed to deliver high-quality patient care. Through its centers management, and technology access service models, extensive optometric relationships, direct to consumer advertising and managed care contracting strength, TLCVision maintains leading positions in Refractive, Cataract and Eye Care markets. Information about vision correction surgery can be found on the TLC Laser Eye Centers website at www.tlcvision.com. More information about TLCVision can be found on the website at www.tlcv.com.

Note that the unaudited, interim consolidated financial statements for the three and twelve months ended December 31, 2006 include certain reclassifications to conform with the business-line and segment classifications for the three and twelve months ended December 31, 2007.

1

CONSOLIDATING STATEMENTS OF OPERATIONS (UNAUDITED)
(In thousands, except per share amounts)
	Three Months Ended December 31, 2007	Three Months Ended December 31, 2006

<root/>

	Results Before AMD											Results Before AMD
	Segment			AMD Segment				Total TLCVision				Segment					AMD Segment				Total TLCVision
Revenues:
Refractive centers	$	36,311			$	-			$	36,311		$			34,652			$	-			$	34,652
Doctor services		23,321				-				23,321					22,411				-				22,411
Eye care		6,662				-				6,662					5,646				-				5,646
Total revenues		66,294				-				66,294					62,709				-				62,709
Cost of revenues (excluding amortization):
Refractive centers		29,383				-				29,383					26,655				-				26,655
Doctor services		17,066				-				17,066					16,529				-				16,529
Eye care		2,940				-				2,940					2,426				-				2,426
Total cost of revenues (excluding amortization)		49,389				-				49,389					45,610				-				45,610
Gross profit		16,905				-				16,905					17,099				-				17,099
General and administrative		8,606				-				8,606					8,550				-				8,550
Marketing and sales		12,389				-				12,389					7,467				-				7,467
Research and development, clinical and regulatory		-				-				-			-						-				-
Amortization of intangibles		844				-				844					865				-				865
Impairment of goodwill and other assets		4,550				-				4,550			-						-				-
Other expenses, net		1,771				-				1,771					781				-				781
Total operating costs		28,160				-				28,160					17,663				-				17,663
Operating loss		(11,255	)			-				(11,255	)				(564	)			-				(564	)
Loss on sale of Occulogix, Inc. stock		-				(34	)			(34	)		-						-				-
Interest income		227				-				227					525				-				525
Interest expense		(2,370	)			-				(2,370	)				(404	)			-				(404	)
Minority interests		(1,979	)			-				(1,979	)				(1,977	)			-				(1,977	)
(Loss) earnings from equity investments		(81	)			(6,573	)			(6,654	)				450				(2,506	)			(2,056	)
(Loss) income from continuing operations before
income taxes		(15,458	)			(6,607	)			(22,065	)				(1,970	)			(2,506	)			(4,476	)
Income tax (expense) benefit		(3,445	)			-				(3,445	)				5,027				-				5,027
(Loss) income from continuing operations		(18,903	)			(6,607	)			(25,510	)				3,057				(2,506	)			551
Income (loss) from discontinued operations, net
of tax		226				-				226					(2,912	)			-				(2,912	)
Net (loss) income	$	(18,677	)		$	(6,607	)		$	(25,284	)	$			145			$	(2,506	)		$	(2,361	)
(Loss) earnigns per share — diluted	$	(0.37	)		$	(0.13	)		$	(0.51	)	$			0.00			$	(0.03	)		$	(0.03	)
Weighted average number of common shares
outstanding — diluted		49,928				49,928				49,928					69,759				69,759				69,759
Calculation of Pro Forma Net Income and EPS
Net (loss) income, as reported	$	(18,677	)									$			145
Add: Non-recurring costs		6,513													5,305
Interest expense from Dutch tender		0													(1,779	)
Adjust income tax expense to 21%		5,275													(5,545	)
Pro forma net (loss) income	$	(6,889	)									$			(1,874	)
Pro forma (loss) earnings per share	$	(0.14	)									$			(0.04	)
Calculation of Pro Forma Total Revenues
Total revenues, as reported	$	66,294										$			62,709
Add: Revenues from Discontinued Operations		665													832
Pro forma total revenues	$	66,959										$			63,541
Note: The AMD segment includes the Company’s interest in OccuLogix, Inc.
TLC VISION CORPORATION
CONSOLIDATING STATEMENTS OF OPERATIONS (UNAUDITED)
(In thousands, except per share amounts)
				Twelve Months Ended December 31, 2007													Twelve Months Ended December 31, 2006
	Results Before AMD											Results Before AMD
	Segment				AMD Segment			Total TLCVision				Segment					AMD Segment				Total TLCVision
Revenues:
Refractive centers	$	174,816			$	-			$	174,816				$	161,822			$	-			$	161,822
Doctor services		97,087				-				97,087					93,171				-				93,171
Eye care		26,511				-				26,511					22,860				-				22,860
Total revenues		298,414				-				298,414					277,853				-				277,853
Cost of revenues (excluding amortization):
Refractive centers		126,804				-				126,804					114,883				-				114,883
Doctor services		70,281				-				70,281					66,662				-				66,662
Eye care		11,999				-				11,999					9,733				1,659				11,392
Total cost of revenues (excluding amortization)		209,084				-				209,084					191,278				1,659				192,937
Gross profit (loss)		89,330				-				89,330					86,575				(1,659	)			84,916
General and administrative		34,819				-				34,819					32,717				1,759				34,476
Marketing and sales		42,979				-				42,979					27,622				169				27,791
Research and development, clinical and regulatory		-				-				-			-						1,475				1,475
Amortization of intangibles		3,398				-				3,398					3,451				-				3,451
Impairment of goodwill and other assets		7,659				-				7,659			-						-				-
Other expenses, net		2,753				-				2,753					25				849				874
Total operating costs		91,608				-				91,608					63,815				4,252				68,067
Operating (loss) income		(2,278	)			-				(2,278	)				22,760				(5,911	)			16,849
Gain on sale of Occulogix, Inc. stock		-				899				899			-						1,450				1,450
Interest income		1,621				-				1,621					1,964				366				2,330
Interest expense		(5,778	)			-				(5,778	)				(1,455	)			-				(1,455	)
Minority interests		(8,921	)			-				(8,921	)				(9,228	)			2,715				(6,513	)
Earnings (losses) from equity investments		1,029				(13,396	)			(12,367	)				3,173				(5,809	)			(2,636	)
(Loss) income from continuing operations before
income taxes		(14,327	)			(12,497	)			(26,824	)				17,214				(7,189	)			10,025
Income tax (expense) benefit		(8,476	)			-				(8,476	)				3,655				-				3,655
(Loss) income from continuing operations		(22,803	)			(12,497	)			(35,300	)				20,869				(7,189	)			13,680
(Loss) income from discontinued operations, net
of tax		(8,214	)			-				(8,214	)				(2,161	)			-				(2,161	)
Net (loss) income	$	(31,017	)		$	(12,497	)		$	(43,514	)	$			18,708			$	(7,189	)		$	11,519
(Loss) earnings per share — diluted	$	(0.53	)		$	(0.21	)		$	(0.74	)	$			0.27			$	(0.10	)		$	0.17
Weighted average number of common shares
outstanding — diluted		59,139				59,139				59,139					69,580				69,580				69,580
Calculation of Pro Forma Net Income and EPS
Net (loss) income, as reported		(31,017	)												18,708
Add: Non-recurring costs		20,987													5,305
Interest expense from Dutch tender		0													(3,829	)
Adjust income tax expense to 21%		8,802													(7,722	)
Pro forma net (loss) income		(1,228	)												12,462
													$
Pro forma (loss) earnings per share	$	(0.02	)										0.21
Calculation of Pro Forma Total Revenues
Total revenues, as reported	$	298,414										$			277,853
Add: Revenues from Discontinued Operations		3,535													3,973
Pro forma total revenues	$	301,949										$			281,826
Note: The AMD segment includes the Company’s interest in OccuLogix, Inc.
TLC VISION CORPORATION
CONSOLIDATING BALANCE SHEETS
(In thousands)
				December 31, 2007													December 31, 2006
	Results Before AMD											Results Before AMD
	Segment				AMD Segment			Total TLCVision				Segment (Unaudited)					AMD Segment (Unaudited)				Total TLCVision
ASSETS
Current assets
Cash and cash equivalents	$	12,925			$	-			$	12,925		$			28,917				-			$	28,917
Short-term investments		-				-				-					11,575				-				11,575
Accounts receivable, net		18,076				-				18,076					19,315				-				19,315
Deferred tax asset		-				-				-					7,153				-				7,153
Prepaid expenses, inventory and other		14,882				-				14,882					13,911				-				13,911
Total current assets		45,883				-				45,883					80,871				-				80,871
Restricted cash		1,101				-				1,101					1,035				-				1,035
Investments and other assets		17,524				-				17,524					24,495				14,362				38,857
Goodwill		94,346				-				94,346					96,148				-				96,148
Other intangible assets, net		17,020				-				17,020					20,503				-				20,503
Fixed assets, net		61,936				-				61,936					56,888				-				56,888
Total assets	$	237,810			$	-			$	237,810		$279,940						$	14,362			$	294,302
LIABILITIES
Current liabilities
Accounts payable	$	17,177				-			$	17,177		$12,314							-			$	12,314
Accrued liabilities		28,115				-				28,115					20,231				-				20,231
Current maturities of long-term debt		11,732				-				11,732					8,311				-				8,311
Total current liabilities		57,024				-				57,024					40,856				-				40,856
Long-term debt, less current maturities		98,417				-				98,417					15,122				-				15,122
Other long-term liabilities		5,023				-				5,023					4,442				-				4,442
Minority interests		15,224				-				15,224					14,583				-				14,583
Total liabilities		175,688				-				175,688					75,003				-				75,003
STOCKHOLDERS’ EQUITY
Common stock		308,972				28,501				337,473					419,767				30,366				450,133
Option and warrant equity		837				-				837					1,806				-				1,806
Other comprehensive income		(784	)			-				(784	)		-						-				-
Accumulated deficit		(246,903	)			(28,501	)			(275,404	)				(216,636	)			(16,004	)	(232,640)
Total stockholders’ equity		62,122				-				62,122					204,937				14,362				219,299
Total liabilities and stockholders’ equity	$	237,810			$	-			$	237,810				$	279,940			$	14,362			$	294,302
Note: The AMD segment includes the Company’s interest in OccuLogix, Inc.
TLC VISION CORPORATION
CONSOLIDATING STATEMENTS OF CASH FLOWS (UNAUDITED)
(In thousands, except per share amounts)
				Twelve Months Ended December 31, 2007													Twelve Months Ended December 31, 2006
	Results Before AMD											Results Before AMD
	Segment				AMD Segment			Total TLCVision				Segment					AMD Segment				Total TLCVision
OPERATING ACTIVITIES
Net (loss) income	$	(31,017	)		$	(12,497	)		$	(43,514	)			$	18,708			$	(7,189	)		$	11,519
Adjustments to reconcile net (loss) income to net
cash from operating activities:
Depreciation and amortization		18,859				-				18,859					16,358				34				16,392
Reimbursements from investments in research and
development
arrangements		-				-				-					(300	)			-				(300	)
Impairment of goodwill and other assets		16,950				-				16,950					4,087				-				4,087
Minority interests		9,423				-				9,423					9,737				(2,715	)			7,022
(Earnings) losses from equity investments		(1,029	)			13,396				12,367					(3,173	)			5,809				2,636
Deferred taxes		6,639				-				6,639					(5,241	)			-				(5,241	)
Excess tax benefits from stock-based compensation
expense		-								-			-
(Gain) loss on sales and disposals of fixed assets		(11	)			-				(11	)				111				29				140
Gain on sale of subsidiary stock		-				(899	)			(899	)				(349	)			(1,450	)			(1,799	)
Write-down of OccuLogix, Inc. inventory		-				-				-			-						1,625				1,625
Loss (gain) on sale of business		233				-				233			-						-				-
Non-cash compensation expense		1,115				-				1,115					1,258				186				1,444
Adjustments to the fair values of long-lived
assets and liabilities		-				-				-					294				-				294
Other		275				-				275					58				26				84
Changes in operating assets and liabilities, net
of acquisitions and dispositions:		9,893				-				9,893					(3,190	)			(1,225	)			(4,415	)
Cash from operating activities		31,330				-				31,330					38,358				(4,870	)			33,488
INVESTING ACTIVITIES
Purchases of fixed assets		(13,279	)			-				(13,279	)				(11,493	)			-				(11,493	)
Proceeds from sales of fixed assets		1,114				-				1,114					681				-				681
Distributions and loan payments received from
equity investments		2,846				-				2,846					3,613				-				3,613
Reimbursements from investments in research and
development
arrangements		-				-				-					300				-				300
Acquisitions and equity investments		(4,815	)			-				(4,815	)				(7,839	)			-				(7,839	)
Proceeds from sales of short-term investments		17,375				-				17,375					400				9,925				10,325
Purchases of short-term investments		(5,800	)			-				(5,800	)				(5,425	)			-				(5,425	)
Proceeds from sale of subsidiary stock, net		2,000				-				2,000					230				2,226				2,456
Divestitures of business		1,619				-				1,619			-						-				-
Occulogix, Inc. cash balance at time of
deconsolidation		-				-				-			-						(14,814	)			(14,814	)
Other		123				-				123					59				(71	)			(12	)
Cash from investing activities		1,183				-				1,183					(19,474	)			(2,734	)			(22,208	)
FINANCING ACTIVITIES
Restricted cash movement		(66	)			-				(66	)				(60	)			-				(60	)
Principal payments of debt financing and capital
leases		(11,998	)			-				(11,998	)				(6,479	)			-				(6,479	)
Proceeds from debt financing		89,717				-				89,717					441				-				441
Capitalized debt costs		(1,960	)			-				(1,960	)		-						-				-
Distributions to minority interests		(9,454	)			-				(9,454	)				(9,197	)			-				(9,197	)
Proceeds from issuances of common stock		2,825				-				2,825					970				-				970
Proceeds from issuances of OccuLogix, Inc. stock		-				-				-			-						233				233
Transfer from AMD segment		-				-				-					2,236				(2,236	)			-
Purchases of treasury stock		(117,569	)			-				(117,569	)		-						-				-
Cash from financing activities		(48,505	)			-				(48,505	)				(12,089	)			(2,003	)			(14,092	)
Net (decrease) increase in cash and cash
equivalents during the period		(15,992	)			-				(15,992	)				6,795				(9,607	)			(2,812	)
Cash and cash equivalents, beginning of period		28,917								28,917					22,122				9,607				31,729
Cash and cash equivalents, end of period	$	12,925			$	-			$	12,925				$	28,917			$	-			$	28,917
Operating cash flow per diluted share	$	0.53			$	-			$	0.53				$	0.55			$	(0.07	)		$	0.48
Note: The AMD segment includes the Company’s interest in OccuLogix, Inc.

2